IL13 and central nervous system cancer: The IL-13 rs1800925 polymorphism was significantly associated with decreased a risk of glioma (CT vs. TT: OR = 0.72, 95% CI 0.55–0.93; CT/TT vs.TT: OR = 0.76, 95% CI 0.62–0.89) [22].